Business Context and Reporting Period
This Form 8-K was filed by Atyr Pharma, Inc. on March 6, 2018. The report addresses a material corporate governance event involving the departure of a senior executive.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes rather than financial performance.
Material Changes
- Executive Departure: John T. Blake, Senior Vice President, Finance, and principal financial and accounting officer, resigned to pursue another opportunity.
- Effective Date: The resignation is effective as of the close of business on the date the Company files its Form 10-K for the year ended December 31, 2017 (anticipated to be March 20, 2018).
- Succession Plan: The Company will promptly begin a search for a replacement and will designate an interim principal financial and accounting officer effective on Mr. Blake's departure date.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed is the temporary absence of a permanent principal financial and accounting officer until a replacement is hired.
Investor Verification Checklist
- Verify the exact date of the Form 10-K filing to confirm the precise effective date of Mr. Blake's resignation.
- Monitor subsequent filings for the appointment of an interim principal financial and accounting officer.
- Review the upcoming Form 10-K for the year ended December 31, 2017, to assess the company's financial position in the absence of the departing CFO.